PharmaTimesNews & Politicsnews

CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment

Tuesday, April 7, 2026John PinchingView original

Study expands development of the antibody into hepatocellular carcinoma

Read the full article on the original site.

Read Full Article